Patents by Inventor Mahan Moshir

Mahan Moshir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD70 COMBINATION THERAPY
    Publication number: 20240002523
    Abstract: The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/1L1RAP and CD47.
    Type: Application
    Filed: November 10, 2022
    Publication date: January 4, 2024
    Inventors: Luc VAN ROMPAEY, Mahan MOSHIR, Tim DELAHAYE, Piotr ZABROCKI
  • ANTIBODIES TO CD70
    Publication number: 20230265201
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: July 11, 2022
    Publication date: August 24, 2023
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • CD70 combination therapy
    Patent number: 11530271
    Abstract: The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/IL1RAP and CD47.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: December 20, 2022
    Assignee: argenx BV
    Inventors: Luc Van Rompaey, Mahan Moshir, Tim Delahaye, Piotr Zabrocki
  • Antibodies to CD70
    Patent number: 11434298
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: September 6, 2022
    Assignee: ARGENX BV
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Antibodies to CD70
    Patent number: 11072665
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 27, 2021
    Assignee: argenx BVBA
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • ANTIBODIES TO CD70
    Publication number: 20190270823
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 18, 2019
    Publication date: September 5, 2019
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • ANTIBODIES TO CD70
    Publication number: 20170369581
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 19, 2015
    Publication date: December 28, 2017
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Antibodies to CD70
    Patent number: 9765149
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Antibodies to CD70
    Patent number: 9765148
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • ANTIBODIES TO CD70
    Publication number: 20150266963
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 19, 2015
    Publication date: September 24, 2015
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Antibodies to CD70
    Patent number: 8834882
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 16, 2014
    Assignee: arGEN-X B.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • ANTIBODIES TO CD70
    Publication number: 20140235843
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: January 24, 2014
    Publication date: August 21, 2014
    Applicant: arGEN-X B.V.
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • ANTIBODIES TO CD70
    Publication number: 20140147450
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 29, 2014
    Applicant: ARGEN-X B.V.
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • ANTIBODIES TO CD70
    Publication number: 20140141016
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: March 16, 2012
    Publication date: May 22, 2014
    Applicant: ARGEN-X B.V.
    Inventors: Karen Silence, Peter Ulrights, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir